Edition:
United Kingdom

Arrowhead Pharmaceuticals Inc (ARWR.OQ)

ARWR.OQ on NASDAQ Stock Exchange Global Select Market

6.28USD
23 Jan 2018
Change (% chg)

$-0.11 (-1.72%)
Prev Close
$6.39
Open
$6.46
Day's High
$6.55
Day's Low
$6.25
Volume
505,019
Avg. Vol
317,558
52-wk High
$6.75
52-wk Low
$1.42

Chart for

About

Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce knockdown of... (more)

Overall

Beta: 1.91
Market Cap(Mil.): $317.78
Shares Outstanding(Mil.): 74.77
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 85.70 16.62
EPS (TTM): -- -- --
ROI: -- 3.19 10.61
ROE: -- 4.52 14.21

BRIEF-Arrowhead Pharmaceuticals Announces Pricing Of Underwritten Public Offering Of Common Stock

* ARROWHEAD PHARMACEUTICALS ANNOUNCES PRICING OF UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK

18 Jan 2018

BRIEF-Arrowhead Pharma Announces Proposed Underwritten Offering Of Common Stock

* ARROWHEAD PHARMACEUTICALS ANNOUNCES PROPOSED UNDERWRITTEN OFFERING OF COMMON STOCK Source text for Eikon: Further company coverage:

17 Jan 2018

BRIEF-Silence Therapeutics ‍Sells Further Stake In Arrowhead Pharmaceuticals ​

* ‍SOLD A FURTHER PART OF ITS HOLDING OF COMMON SHARES IN ARROWHEAD PHARMACEUTICALS INC.​

28 Dec 2017

BRIEF-Arrowhead Pharmaceuticals Files For Regulatory Clearance To Begin Phase 1/2 Study Of ARO-HBV

* ARROWHEAD PHARMACEUTICALS FILES FOR REGULATORY CLEARANCE TO BEGIN PHASE 1/2 STUDY OF ARO-HBV Source text for Eikon: Further company coverage:

22 Dec 2017

BRIEF-Arrowhead Pharmaceuticals Files For Regulatory Clearance To Begin Phase 1 Study Of ARO-AAT

* ARROWHEAD PHARMACEUTICALS FILES FOR REGULATORY CLEARANCE TO BEGIN PHASE 1 STUDY OF ARO-AAT

20 Dec 2017

BRIEF-Silence Therapeutics Says Sold Further Part Of Holding In Arrowhead Pharmaceuticals Inc

* HAS SOLD A FURTHER PART OF ITS HOLDING OF COMMON SHARES IN ARROWHEAD PHARMACEUTICALS INC.

11 Dec 2017

BRIEF-Silence Therapeutics Says Sold Part Of Holding Of Common Shares In Arrowhead Pharmaceuticals

* THAT IT HAS SOLD PART OF ITS HOLDING OF COMMON SHARES IN ARROWHEAD PHARMACEUTICALS INC​

04 Dec 2017

BRIEF-Silence Therapeutics Plc Reports 6.4 Pct Stake In Arrowhead Pharmaceuticals As Of Nov 29

* SILENCE THERAPEUTICS PLC REPORTS 6.4 PERCENT STAKE IN ARROWHEAD PHARMACEUTICALS INC AS OF NOVEMBER 29 - SEC FILING

01 Dec 2017

BRIEF-Arrowhead Qtrly loss per share $0.07

* Qtrly revenue $9.3 million versus $39,583 Source text for Eikon: Further company coverage:

03 Aug 2017

Earnings vs. Estimates